Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Medicine (Baltimore) ; 101(7): e28856, 2022 Feb 18.
Article in English | MEDLINE | ID: covidwho-1735689

ABSTRACT

ABSTRACT: Coronavirus disease 2019 (COVID-19) was first detected in China in December 2019, and declared as a pandemic by the World Health Organization (WHO) on March 11, 2020.To study the clinical features of patients with COVID-19, we analyzed the correlation between some inflammation-related indicators in patients' serum and the severity of the disease, especially PV (pneumonia volume under CT scan) and pneumonia volume ratio (PVR).Sixty-six COVID-19 patients in Huai'an, China were selected as the research subjects. We collected the clinical data, including general characteristics, clinical symptoms, serum test results and CT performance, explored the relationship between inflammation-related indexes, oxygenation index, PV, PVR, while indicators of mild to moderate patients and severe patients were compared.The most prominent manifestations of COVID-19 patients were fever (47, 71.2%); cough (41, 62.1%), with or without respiratory and other systemic symptoms; There was no difference in gender (P = .567) and age (P = .865) between mild to moderate and severe groups. High sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), and interleukin-6 (IL-6) of overall patients were higher than the normal range (P < .001, respectively). hs-CRP was negatively correlated with oxygenation index (OI) (r = -0.55), whereas positively correlated with PV, PVR and ESR (r = 0.89; r = 0.87; r = 0.47, respectively); ESR was negatively correlated with OI (r = -0.45), meanwhile it was positively correlated with PV and PVR (r = 0.44; r = 0.46, respectively). OI was negatively correlated with PV and PVR (r = -0.6, respectively). PV had a clear correlation with PVR (r = 1). Severe patients' hs-CRP, PV, PVR were higher than mild to moderate group (P = .006; P = .001; P < .001, respectively), but OI was lower (P < .001).The clinical features of COVID-19 were similar to general viral pneumonia. hs-CRP, ESR showed a certain correlation with the PV and PVR, which might play a certain role in assessing the severity of COVID-19.


Subject(s)
COVID-19 , Pneumonia , Blood Sedimentation , C-Reactive Protein/analysis , Humans , Inflammation
2.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-324132

ABSTRACT

Background: Coronavirus disease 2019 (COVID-19) has brought major harm and challenges to the world. Although many studies have suggested that IFN-I could affect the life cycle of the virus by regulating the expression level of microRNAs, the expression characteristics of plasma IFN-I signaling-related miRNAs at the acute and recovery phase of COVID-19 remain unclear.MethodsDemographic characteristics and fasting blood samples were collected from the acute and recovery phases of 29 COVID-19 patients and 29 healthy controls matched by age (± 5years) and gender (1:1). Expression levels of 12 IFN signaling-related miRNAs were analyzed using RT-qPCR. The receptor-binding domain (RBD) IgG antibody in the convalescent plasma samples was detected using competitive ELISA.ResultsCompared with healthy controls, patients with COVID-19 presented increased levels of miR-29b-3p (~ 5.91-fold), miR-497-5p (~ 2.28-fold), and miR-1246 (~ 7.97-fold), and decreased expression levels of miR-186-5p (~ 6.39-fold) and miR-15a-5p (~ 3.26-fold) at the acute phase of infection. However, the expression levels of miR-29b-3p and miR-1246, which significantly elevated at the acute phase, were not different between individuals at the recovery phase and healthy controls. The expression levels of miR-30b-5p, miR-497-5p, miR-409-3p and miR-548c-5p in convalescent plasma samples were significantly lower than those in healthy controls. However, the concentration of miR-186-5p in the convalescent plasma samples was significantly higher than that in healthy controls and patients with acute infection. Furthermore, competitive ELISA results showed that the plasma level of miR-497-5p at the acute phase positively correlated with RBD-IgG antibody response (r=0.48, P =0.038).ConclusionsThe present study firstly reported that timely and appropriate regulation of IFN signaling-related miRNA expression plays a critical role during both acute and recovery phase of SARS-CoV-2 infection. Furthermore, the circulating miR-497-5p level was positively correlated to RBD-IgG antibody response in COVID-19 patients.

3.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-323646

ABSTRACT

Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a new emerging public health crisis to the world. However, data are still limited on the clinical features and laboratory findings in COVID-19 patients. Methods: : Medical records including demographics characteristics, clinical features, laboratory findings and radiological materials of 66 hospitalized COVID-19 patients were collected between Jan 23 and Mar 9, 2020. Symptoms/signs with potential association with the disease severity were analyzed. Results: : Of 66 hospitalized COVID-19 patients, the male-to-female ratio was 44:22. There were eight cases potentially exposed to one single patient. The most common initial symptoms of SARS-CoV-2 infection were fever (77.3%) and cough (74.2%). Compared to those with non-severe infection, the severe patients were more likely to be older (62.6 ± 15.1 vs 46.9 ± 13.3 years. P = 0.001) and with more infected lobes. As the results shown, higher initial (on admission) and peak (during hospitalization) counts of lymphocyte were inversely associated with the severe SARS-CoV-2 infection (both OR: 0.01 every 1´10 9 /L decrease). However, the elevated initial neutrophil counts (OR: 1.63 every 1´10 9 /L increase), initial and peak levels of LDH (OR: 1.02 and 1.01 every 1 U/L increase), peak levels of CRP (OR: 1.03 every 1 mg/L increase), AST (OR: 1.06 every 1 U/L increase) and ALT (OR: 1.02 every 1 U/L increase) were significantly associated with COVID-19 severity. Conclusion: Our present study indicated that fever and cough were the most common initial symptoms of SARS-CoV-2 infection, and the virus could be efficiently spread by person-to-person transmission. In addition, lymphocyte and neutrophil counts, and serum levels of AST, ALT, CRP and LDH should be useful for the evaluation on COVID-19 severity.

4.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-315681

ABSTRACT

As of August15, 2020, more than 21,155,600 people were infected and about 761,264 were expired due to SARS-CoV-2 infection worldwide. The extreme spread of the emerging virus makes the disease a serious problem for public health. However, a curative treatment or effective specific vaccine againstSARS-CoV-2 infection is unavailable. Recently, several studies have been performed to evaluate the effects of COVID-19 convalescent plasma transfusion on the clinical outcomes in patients with severe/critical COVID-19 [1-5]. However, the results from these studies aredatable, and thus its useremains investigational.

5.
Virol J ; 18(1): 244, 2021 12 07.
Article in English | MEDLINE | ID: covidwho-1559217

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a huge challenge worldwide. Although previous studies have suggested that type I interferon (IFN-I) could inhibit the virus replication, the expression characteristics of IFN-I signaling-related miRNAs (ISR-miRNAs) during acute severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and its relationship with receptor-binding domain (RBD) IgG antibody response at the recovery phase remain unclear. METHODS: Expression profiles of 12 plasma ISR-miRNAs in COVID-19 patients and healthy controls were analyzed using RT-qPCR. The level of RBD-IgG antibody was determined using the competitive ELISA. Spearman correlation was done to measure the associations of plasma ISR-miRNAs with clinical characteristics during acute SARS-CoV-2 infection and RBD-IgG antibody response at the recovery phase. RESULTS: Compared with the healthy controls, COVID-19 patients exhibited higher levels of miR-29b-3p (Z = 3.15, P = 0.002) and miR-1246 (Z = 4.98, P < 0.001). However, the expression of miR-186-5p and miR-15a-5p were significantly decreased. As the results shown, miR-30b-5p was negatively correlated with CD4 + T cell counts (r = - 0.41, P = 0.027) and marginally positively correlated with fasting plasma glucose in COVID-19 patients (r = 0.37, P = 0.052). The competitive ELISA analysis showed the plasma level of miR-497-5p at the acute phase was positively correlated with RBD-IgG antibody response (r = 0.48, P = 0.038). CONCLUSIONS: Our present results suggested that the expression level of ISR-miRNAs was not only associated with acute SARS-CoV-2 infection but also with RBD-IgG antibody response at the recovery phase of COVID-19. Future studies should be performed to explore the biological significance of ISR-miRNAs in SARS-CoV-2 infection.


Subject(s)
Antibodies, Viral/immunology , COVID-19/diagnosis , Immunoglobulin G/immunology , Interferon Type I/genetics , MicroRNAs , Virus Replication/genetics , COVID-19/blood , COVID-19 Nucleic Acid Testing , Case-Control Studies , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Immunoglobulin G/blood , Interferon Type I/blood , Male , MicroRNAs/blood , MicroRNAs/genetics , MicroRNAs/metabolism , Middle Aged , Pregnancy , SARS-CoV-2
7.
Diabetes Obes Metab ; 22(10): 1907-1914, 2020 10.
Article in English | MEDLINE | ID: covidwho-648510

ABSTRACT

AIM: To evaluate the influence of diabetes on the severity and fatality of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. MATERIALS AND METHODS: The medical records of 66 hospitalized coronavirus disease 2019 (COVID-19) patients were collected and classified into non-severe (mild/moderate cases) and severe (severe/critical cases) groups. Logistic regression analysis was used to estimate the risk of severe COVID-19 (severe/critical infection). In addition, a meta-analysis including published studies reported the impact of diabetes on the severity and fatality of COVID-19. The current study was conducted using fixed effects models. RESULTS: There were 22 diabetes and 44 non-diabetes cases among the 66 hospitalized COVID-19 patients. Seven patients with diabetes (31.82%) were diagnosed as severe COVID-19 cases, which was significantly higher than that in the non-diabetes group (4/44, 9.09%, P = .033). After adjustment for age and gender, diabetes was significantly associated with COVID-19 severity (OR: 5.29, 95% CI: 1.07-26.02). A meta-analysis further confirmed the positive association between diabetes and COVID-19 severity (pooled OR = 2.58, 95% CI: 1.93-3.45). Moreover, the patients with diabetes infected with SARS-CoV-2 had a 2.95-fold higher risk of fatality compared with those patients without diabetes (95% CI: 1.93-4.53). CONCLUSIONS: Our findings provide new evidence that diabetes is associated with a higher risk of severity and fatality of COVID-19. Therefore, intensive monitoring and antidiabetic therapy should be considered in patients with diabetes with SARS-CoV-2 infection.


Subject(s)
COVID-19/mortality , COVID-19/pathology , Diabetes Mellitus/mortality , Adult , Aged , COVID-19/complications , COVID-19/therapy , China/epidemiology , Diabetes Complications/epidemiology , Diabetes Complications/mortality , Diabetes Complications/pathology , Diabetes Mellitus/epidemiology , Diabetes Mellitus/pathology , Diabetes Mellitus/therapy , Female , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Pandemics , SARS-CoV-2/physiology , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL